Researcher
Rik
- Keywords:Medicine
- Disciplines:Natural sciences
Affiliations
- Hematology (Department)
Member
From1 Jul 2012 → Today - Hematology (Research group)
Member
From1 Oct 2003 → Today - Clinical sciences (Department)
Member
From8 Apr 2019 → Today - Clinical sciences (Department)
Member
From1 Jan 2014 → 20 Oct 2022 - Laboratory of Molecullar and Cellular Therapy (Research group)
Member
From28 Feb 2013 → 1 Oct 2019 - Immunology and Microbiology (Department)
Member
From1 Dec 2006 → 31 Dec 2013 - Immunology and Microbiology (Department)
Member
From1 Dec 2003 → 30 Sep 2006
Publications
41 - 50 of 56
- No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients
Authors: U Thiel, A Wawer, P Wolf, M Badoglio, A Santucci, T Klingebiel, O Basu, A Borkhardt, H-J Laws, Y Kodera, et al.
Pages: 1614-1621 - VMP in Renally Impaired Newly Diagnosed MM Patients: Cohort Analysis of the VISTA Study
Authors: Ma Dimopoulos, Pg Richardson, R Schlag, Nk Khuageva, O Shpilberg, Efstathios Kastritis, M. Kropff, Mt Petrucci, M. Delforge, Julia Alexeeva, et al.
Pages: 29-29 - Updated Follow-up and Results of Subsequent Therapy in the Phase III VISTA Trial: Bortezomib Plus Melphalan-Prednisone Versus Melphalan-Prednisone in Newly Diagnosed Multiple Myeloma
Authors: Jésus F. San Miguel, R Schlag, Nk Khuageva, Ma Dimopoulos, O Shpilberg, M. Kropff, I. Spicka, Mt Petrucci, A. Palumbo, Os Samoilova, et al.
Pages: 242-242 - Superior survival with VMP versus MP after longer follow-up ans response to subsequent therapy in VISTA
Authors: Jésus F. San Miguel, Ma Dimopoulos, R Schlag, Nk Khuageva, O Shpilberg, M. Kropff, I. Spicka, Mt Petrucci, A. Palumbo, Os Samoilova, et al.
Pages: 39-40 - Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial.
Authors: Mv Mateos, Pg Richardson, R Schlag, Nk Khuageva, Ma Dimopoulos, O Shpilberg, M. Kropff, I. Spicka, Mt Petrucci, A. Palumbo, et al.
Pages: 2259-2266 - A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP
Authors: J.l. Harousseau, R. Niesvizky, A. Palumbo, Pg Richardson, R Schlag, Ma Dimopoulos, O Shpilberg, M. Kropff, M. Delforge, Rik Schots, et al.
Pages: 40-40 - Continuous lenalidomide treatment for newly diagnosed multiple myeloma
Authors: A. Palumbo, R. Hajek, M. Delforge, M. Kropff, Mt Petrucci, J Catalano, H Gisslinger, Wiesław Wiktor-Jędrzejczak, Mamia Zodelava, Katja Weisel, et al.
Pages: 1759-1769 - Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
Authors: Ruth Pettengell, N. Schmitz, Christian Gisselbrecht, Greame Smith, William N Patton, Bernd Metzner, Dolores Caballero, Hervé Tilly, Jan A. Walewski, Isabelle Bence-Bruckler, et al.
Pages: 1624-1630 - New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the international myeloma working group (imwG)
Authors: Em Ocio, Pg Richardson, S. Vincent Rajkumar, A. Palumbo, Mv Mateos, Rz Orlowski, Sk Kumar, S Usmani, David Roodman, R. Niesvizky, et al.
Pages: 525-542 - Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years
Authors: A Necchi, R Miceli, M Bregni, C. Bokemeyer, L A Berger, K Oechsle, K Schumacher, E Kanfer, J.h. Bourhis, C Massard, et al.
Pages: 384-390